ETC-1002 or placebo
ETC-1002-002
Phase 1 small_molecule completed
Quick answer
ETC-1002 or placebo for Mild Dyslipidemia is a Phase 1 program (small_molecule) at Esperion Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Esperion Therapeutics
- Indication
- Mild Dyslipidemia
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed